GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Nhu Co Ltd (SZSE:002001) » Definitions » 3-Year EBITDA Growth Rate

Zhejiang Nhu Co (SZSE:002001) 3-Year EBITDA Growth Rate : 0.30% (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Nhu Co 3-Year EBITDA Growth Rate?

Zhejiang Nhu Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.37.

During the past 12 months, Zhejiang Nhu Co's average EBITDA Per Share Growth Rate was -2.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 0.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 9.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Zhejiang Nhu Co was 140.00% per year. The lowest was -16.00% per year. And the median was 14.90% per year.


Competitive Comparison of Zhejiang Nhu Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Nhu Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Nhu Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Nhu Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Zhejiang Nhu Co's 3-Year EBITDA Growth Rate falls into.



Zhejiang Nhu Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Zhejiang Nhu Co  (SZSE:002001) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Zhejiang Nhu Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Zhejiang Nhu Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Nhu Co (SZSE:002001) Business Description

Traded in Other Exchanges
N/A
Address
No. 4 Jiangbei Road, Yulin Street, Xinchang County, Zhejiang Province, Shaoxing, CHN, 312500
Zhejiang Nhu Co Ltd is a China-based company engaged in the manufacture and sales of pharmaceuticals, health protection products, pharmaceutical intermediates, fragrances, food additives and feed additives. The company's active pharmaceutical ingredient products cover various areas such as Cardiovascular, Anti-AIDS, Anti-cancer and Anti-bacterial with key products such as Latamoxef Sodium, Flomoxef Sodium, Hydrochloride Moxifloxacin, Artemisinin series, Calcium Keto acid series, Vitamin A/E/D3 and coenzyme Q10 and others. The other business areas are Aroma chemicals, Polymers, and Nutrition. The organization markets its products in China and internationally.

Zhejiang Nhu Co (SZSE:002001) Headlines

No Headlines